Callio Therapeutics, a biotech startup aiming to overcome treatment resistance in cancer, has raised $238.0M in a Series A funding round. The significant capital will advance its pipeline of next-generation antibody-drug conjugates (ADCs).
The company is pioneering dual-payload ADCs, a technology designed to drive deeper, more durable responses in patients. While first-generation ADCs have transformed cancer treatment, many patients still progress, highlighting an urgent need for the better therapies Callio is built to deliver.
.png&w=3840&q=75)
